Skip to content

News

OCRF Research Shows Targeting microRNA May Benefit Some Ova...

OCRF Research Shows Targeting microRNA May Benefit Some Ovarian Cancer Patients

(December 10, 2014) OCRF Ann Schreiber Mentored Investigator Award Grantee, Pradeep Chaluvally-Raghavan, Ph.D., and other researchers at The University of Texas MD Anderson Cancer Center believe they may have found a molecule-based approach to halting the destructive nature of a genetic misfire called the 3q26.2 amplicon.  The research was funded in part by a grant … Continued

Population Screening for BRCA Mutations in Ashkenazi Jewish...

Population Screening for BRCA Mutations in Ashkenazi Jewish Women is Cost-Effective

Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. A new study published in the Journal of the National Cancer Institute compared the cost-effectiveness of population-based BRCA testing with the standard FH-based approach in Ashkenazi Jewish (AJ) women. The study found that population-based … Continued

FDA Approves Genentech's Avastin Plus Chemotherapy to ...

FDA Approves Genentech's Avastin Plus Chemotherapy to Treat Women With Platinum-Resistant Recurrent Ovarian Cancer

Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. The approval was based on results from a study that showed Avastin plus chemotherapy reduced the risk of disease worsening or … Continued

Bevacizumab Plus Fosbretabulin Improves Progression-Free Su...

Bevacizumab Plus Fosbretabulin Improves Progression-Free Survival in Ovarian Cancer Patients

The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society. A study found significant improvement in progression-free survival among patients treated with … Continued

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group. Analysts said oncologists expect the drug to have little or … Continued

Diet May Influence Ovarian Cancer Survival

Diet May Influence Ovarian Cancer Survival

According to a new study published in the Journal of the National Cancer Institute, a good diet before diagnosis is linked with lower mortality among ovarian cancer survivors. Researchers analyzed data from 636 cases of ovarian cancer among postmenopausal women within the Women’s Health Initiative Observational Study or Clinical Trials from 1993 to 1998. The … Continued

Use of Intensive Medical Services for Ovarian Cancer Patien...

Use of Intensive Medical Services for Ovarian Cancer Patients at End of Life Increases Despite Rise in Use of Hospice

There have been widespread efforts to improve the quality of life of terminally ill patients. As more patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. A large new study by Dana-Farber Cancer Institute researchers … Continued

Telomere Length and Mortality Following An Ovarian Cancer D...

Telomere Length and Mortality Following An Ovarian Cancer Diagnosis

Telomeres are essential for the maintenance of chromosomal integrity. Telomere shortening leads to genomic instability, which is hypothesized to play a role in cancer development and prognosis. New data published in Cancer Epidemiology, Biomarkers & Prevention, provide preliminary evidence that telomere length likely does not predict outcome after a diagnosis of ovarian cancer. This represents … Continued

Detection of Gene Mutations in Tampons of Patients With Hig...

Detection of Gene Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer

(October 14, 2014) In a pilot study published in the journal Obstetrics & Gynecology, researchers detected DNA derived from tumor cells in the vaginas of 60% of patients with ovarian cancer with intact fallopian tubes. With further development, this approach may hold promise for the early detection of this deadly disease. Click here to read … Continued

Ovarian Cancer Oncogene Found in ‘Junk DNA’

Ovarian Cancer Oncogene Found in ‘Junk DNA’

(October 6, 2014) A research team based at the University of Pennsylvania mined junk DNA sequences to identify a non-protein-coding RNA whose expression is linked to ovarian cancer.  The study, which was published in Cancer Cell, was supported in part by an OCRF research grant to Lin Zhang, MD. The researchers built a DNA copy … Continued

SGO Perspectives on Endpoints for Studies of Ovarian Cancer

SGO Perspectives on Endpoints for Studies of Ovarian Cancer

(Sept. 29, 2014) In a perspective piece for the website MedPage Today, representatives from the Society of Gynecologic Oncology discuss clinical endpoints appropriate for studies addressing the “unique characteristics” of ovarian cancer and progress toward improving outcomes for women affected by the disease. In the article, co-authors Thomas J. Herzog, MD, of the University of Cincinnati … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.